百濟神州(06160.HK)治療淋巴瘤藥品臨床數據更新
百濟神州(06160.HK)公布,公司日前公佈其抗PD-1抗體替雷利珠單抗在中國開展的三項臨床試驗結果,共有七項替雷利珠單抗數據的口頭報告在第22屆中國臨床腫瘤學會年會上被公布,其中五項是有關全新或更新的數據。
此外,另有替雷利珠單抗、澤布替尼、pamiparib的臨床數據在四項海報中被展示。其中,雷利珠單抗在內地獲批用於治療經典型霍奇金淋巴瘤和尿路上皮癌。截至數據截點2019年2月25日,54位患者接受了替雷利珠單抗治療,中位治療時間為38.4周(3-79)。14位患者截至數據截點仍在接受治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.